Evoke Pharma Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
24,196.70
14,155.80
8,691.20
9,007.10
7,679.30
5,319
Other Current Assets
234.30
1,092.90
833.30
275.70
251.00
329.20
Total Current Assets
24,431.00
15,248.70
9,524.40
9,282.80
7,930.30
5,648.20
Other Assets
555.50
53.00
8.00
11.60
11.60
11.60
Total Assets
24,986.50
15,301.70
9,532.40
9,294.30
7,941.90
5,659.80
ST Debt & Current Portion LT Debt
1,442.60
150.40
146.10
-
-
Accounts Payable
284.90
1,011.60
-
-
-
Other Current Liabilities
557.40
709.60
1,688.40
1,411.70
2,074.80
Total Current Liabilities
2,284.90
1,871.60
1,834.40
1,411.70
2,074.80
Long-Term Debt
1,511.50
4,241.40
4,233.10
-
-
Other Liabilities
6.80
-
-
4,095.00
3,701.30
Total Liabilities
3,803.20
6,113.10
6,067.50
5,506.70
5,776.10
Common Equity (Total)
21,183.30
9,188.70
3,464.90
3,787.60
2,165.70
Total Shareholders' Equity
21,183.30
9,188.70
3,464.90
3,787.60
2,165.70
Total Equity
21,183.30
9,188.70
3,464.90
3,787.60
2,165.70
Liabilities & Shareholders' Equity
24,986.50
15,301.70
9,532.40
9,294.30
7,941.90

About Evoke Pharma

View Profile
Address
420 Stevens Avenue
Solana Beach California 92075
United States
Employees -
Website http://www.evokepharma.com
Updated 07/08/2019
Evoke Pharma, Inc. is a pharmaceutical company, which engages in the development of drugs for the treatment of gastrointestinal disorders and diseases. It develops Gimoti, with promotility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus. The company was founded by Matthew J.